Management of recurrent hepatitis C in orthotopic liver transplant recipients

Geeta S. Karnik, Kirti Shetty

Research output: Contribution to journalReview articlepeer-review


End-stage liver disease and hepatocellular carcinoma from chronic hepatitis C are the most common indications for orthotopic liver transplantation and the incidence of both are projected to increase over the next decade. Recurrent hepatitis C virus infection of the allograft is associated with an accelerated progression to cirrhosis, graft loss, and death. This article presents an overview of the natural history of hepatitis C virus recurrence in liver transplant recipients and guidance on optimal management strategies.

Original languageEnglish (US)
Pages (from-to)285-304
Number of pages20
JournalInfectious disease clinics of North America
Issue number2
StatePublished - Jun 2013


  • Direct-acting antivirals
  • Hepatitis C virus
  • Immunosuppression
  • Liver transplant
  • Recurrence

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases


Dive into the research topics of 'Management of recurrent hepatitis C in orthotopic liver transplant recipients'. Together they form a unique fingerprint.

Cite this